OSE Immunotherapeutics and GERCOR Oncology Clinician Group Announce Completion of Patient Enrollment in TEDOPaM Phase 2 Clinical Trial with Tedopi in Advanced Pancreatic Cancer (GERCOR D17-01 PRODIGE 63 trial)
A total of 136 patients were recruited in the Phase 2 trial sponsored and conducted by the French GERCOR Oncology Clinician Group, with the PRODIGE Intergroup and the supply of Tedopi® by OSE Immunotherapeutics.
Source: finanznachrichten.de